The medical software and services group said the agreement would provide its products with “extended and immediate” sales representation in the US and other international markets, while CorTech would add IB’s software and exclusive algorithms to its portfolio.
The product suite includes IB’s StoneChecker software, which helps analyse kidney stones, as well as IB Neuro which provides tumour biology data and the IB Delta Suite which helps clinicians distinguish tumour progression from treatment effects.
IQ-AI said IB’s products would complement those of CorTechs, which specialises in assessing neurological conditions, including Alzheimer's disease, multiple sclerosis, epilepsy and traumatic brain injury.
David Smith, IB’s chief executive, said the deal meant IQ-AI’s products would have “direct sales representation worldwide” for the first time, and that the firm was “very excited” about the shared revenue potential of the agreement.
“CorTechs Labs has a well established and rapidly growing sales and marketing team who can introduce IB's portfolio to their existing and new clients”, he added.
In mid-afternoon the shares were 8.3% higher at 1.3p.
--Adds share price--